“Our cancer cure will be effective from day one.”

A team of Isreali doctors has made the bold claim that they will have a “complete cure” for cancer in a year’s time.

The Jerusalem Post spoke with Dan Aridor about the new cancer treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor told the paper. “Our solution will be both generic and personal.”

Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, told the Post that their treatment, which they call MuTaTo (multi-target toxin), is essentially on the scale of a cancer antibiotic.

One of the key components to MuTaTo’s success, claims AEBi, is the treatments use of a combination of multiple cancer-targeting peptides for each cancer cell at the same time and delivered along with a strong peptide toxin that specifically kills cancer cells.

By using at multiple targeting peptides on the same cell with a strong toxin, Morad said, “we made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer.”

Other treatments have failed because most anti-cancer drugs target only one specific target and when a mutation occurs the drug attacking it is ineffective. MuTaTo’s multi-peptide approach is an attempt to solve this problem.

“The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used,” Morad continued. “Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”

The strong toxin MuTaTo delivers along with the multi-peptide approach will also ensure that cancer stem cells are destroyed, where most cancer mutations arise from and are not always fully eradicated by cancer treatments.

Morad also told the Post that side effects should be less severe as the treatment won’t target healthy cells or the wrong targets on cancerous cells, both problems can lead to unwanted side-effects.

MuTaTo’s approach is akin to the change in the medical approach to HIV when doctors started treating HIV patients with a cocktail of drugs which allowed them to live with and effectively manage the disease.

“We used to give AIDS patients several drugs, but we would administer them one at a time,” Morad explained to the Post. “During the course of treatment, the virus mutated, and the AIDS started attacking again. Only when patients started using a cocktail, were they able to stop the disease.”

However, unlike the treatment for AIDS, Morad said that patients could likely stop taking the cancer cocktail after only a few weeks because the cancer cells would be killed.

AEBi has completed successful trials on mice and claimed to the Post that their “results are consistent and repeatable.”